- Home
- SLS vs REF Comparison
SLS vs REF Comparison
Compare SLS & REF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$13.41
N/A
Current Price
$15.04
Company Overview
Basic Information| Metric | SLS | REF |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.5M | 958.2M |
| IPO Year | 2007 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SLS | REF |
|---|---|---|
| Price | $13.41 | $15.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 464.7K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $110.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $12.83 |
| 52 Week High | $15.88 | $17.26 |
Technical Indicators
Market Signals| Indicator | SLS | REF |
|---|---|---|
| Relative Strength Index (RSI) | 55.17 | 45.47 |
| Support Level | $11.43 | $12.83 |
| Resistance Level | $15.77 | $16.74 |
| Average True Range (ATR) | 1.19 | 0.86 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 62.22 | 60.36 |
Price Performance
Historical Comparison SLS
REF
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.